Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
CDXS Stock Chart & Stats
$1.64
-$0.29(-5.81%)
At close: 4:00 PM EST
$1.64
-$0.29(-5.81%)
Day’s Range― - ―
52-Week Range$1.59 - $6.08
Previous CloseN/A
Volume271.47K
Average Volume (3M)554.79K
Market Cap
$195.88M
Enterprise Value$210.50M
Total Cash (Recent Filing)$59.19M
Total Debt (Recent Filing)$68.62M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Feb 26, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding90,267,460
10 Day Avg. Volume608,232
30 Day Avg. Volume554,794
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.23
Price to Sales (P/S)5.90
P/FCF Ratio-6.52
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue3.98
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda-3.81
Forecast
1Y Price Target
$6.00Price Target Upside265.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Customer Base ExpansionCodexis has expanded its customer base by adding 10 new commercial customers this year with 40 prospects in the pipeline.
Financial StabilityThe company has secured a cash runway for operations through 2027, supported by the expected funds from the Merck agreement.
Strategic AgreementsA $37.8 million supply assurance agreement with Merck is expected to significantly boost Codexis's revenues in the upcoming quarter.
Bears Say
Leadership ChangesCEO Stephen Dilly and COO Kevin Norrett will both transition out of their current roles, adding significant uncertainty.
Product Transition ChallengesCodexis is de-emphasizing their legacy small molecule biocatalysis business, citing pricing pressure and low return on investment, which adds to uncertainty.
Workforce ReductionThe company announced the elimination of 46 positions or 24% of the company’s workforce.
Codexis News
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $1.59 and its highest was $6.08 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $195.88M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Feb 26, 2026 which is in 98 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Nov 06, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.071.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.06.
How many shares outstanding does Codexis have?
Codexis has 90,267,460 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went down -17.157%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
Codexis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (265.85% Upside)
$6.00 (265.85% Upside)
Hedge Fund Trend
Decreased
By 51.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.36%
12-Months-Change
Fundamentals
Return on Equity
-114.26%
Trailing 12-Months
Asset Growth
4.73%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Company Deck
CDXS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic achievements, particularly the Merck agreement and growth in the ECO Synthesis platform. These were offset by challenges in revenue decline, net losses, and the shift away from the small molecule biocatalysis business. The sentiment remains cautiously optimistic as the company transitions with new leadership and strategic focus.View all CDXS earnings summariesCDXS Stock 12 Month Forecast
Average Price Target
$6.00
▲(265.85% Upside)
Technical Analysis
Ownership Overview
14.30% Insiders
15.04% Mutual Funds
31.35% Other Institutional Investors
30.01% Public Companies and
Individual Investors